Welcome back! Before we talk about cellcept for lupus nephritis, I decided we should flash back to 1996 and discuss one of the early trials that brought us cyclophosphamide. It's a quick discussion that will help set us up nicely for ALMS this Sunday. Remember to follow us on Twitter @JBRheum for updates! Access the paper here.
Entries from January 2018
E6: Methylprednisolone and Cyclophosphamide, Alone or in Combinatinon, for Lupus Nephritis
January 31st, 2018 · Comments
Tags: DefaultTag
E5: Allopurinol at 1st Medical Contact for Acute Gout - An RCT
January 28th, 2018 · Comments
This week we'll be discussing a trial addressing a controversial topic - starting allopurinol during an acute attack of gout. It's a short podcast on a short paper, but one that could have a big impact on your practice. Be sure to follow us on Twitter @EBRheum! Access the paper itself here.
Tags: DefaultTag
E4: Myeloablative SCT for Scleroderma - The SCOT Trial
January 26th, 2018 · Comments
This week we'll be discussing the recent SCOT trial, which pitting myeloablative autologous stem cell transplant against standard care of cyclophosphamide. Be sure to follow us on Twitter at @EBRheum and checkout @RheumJC for a great online discussion of the trial! Access the paper itself here: https://tinyurl.com/y9xdkvzs
Tags: DefaultTag
Episode 3 - Hydroxychloroquine for Sjogrens Disease - The JOQUER RCT
January 24th, 2018 · Comments
Today we discuss the 2014 JOQUER paper, a randomized controlled trial of hydroxychloroquine (plaquenil) vs. placebo. You can find the paper here: https://tinyurl.com/ydbb6to9
Tags: jama · acr · sjogrens · RCT
Episode 2 - The Evidence Basis for the ACR Practice Guidelines
January 11th, 2018 · Comments
Today we discuss a recent letter in JAMA-Internal medicine. Find the original paper here and be sure to subscribe to the podcast!
Tags: guidelines · jama · acr
Episode 1 - Introduction
January 4th, 2018 · Comments
Welcome to the Evidence Based Rheumatology Podcast! A (very) brief introduction to the podcast.
Tags: DefaultTag